What’s Trending?

Includes data for head and neck cancer, biliary tract cancer and esophageal cancers [...]
Mon, Oct 22, 2018
Source PharmaTimes
Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost, according to an analyst. [...]
Mon, Oct 22, 2018
Source FiercePharma
MSD's immunotherapy improved overall survival by up to 39% [...]
Mon, Oct 22, 2018
Source PharmaTimes
Bristol-Myers Squibb presented a raft of results for its Opdivo-Yervoy immuno-oncology combo across multiple tumor types at the European Society for Medical Oncology meeting. But results it didn't present stole the weekend spotlight. [...]
Mon, Oct 22, 2018
Source FiercePharma
Merck KGaA has opened a new distribution center as it continues to streamline its manufacturing and build up the production site at its headquarters in Darmstadt, Germany. [...]
Mon, Oct 22, 2018
Source FiercePharma
After batting aside efficacy questions in head and neck cancer, Merck's Keytruda is back with a new batch of positive data, this time in previously untreated patients. [...]
Mon, Oct 22, 2018
Source FiercePharma
Drug improved progression-free survival by 70% [...]
Mon, Oct 22, 2018
Source PharmaTimes
Positive results in lung and breast cancer, but Roche is still playing catch-up to rival drugs [...]
Mon, Oct 22, 2018
Source PharmaTimes
Amgen
Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. [...]
Fri, Oct 19, 2018
Source WorldPharmaNews
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD). Researchers at the Westmead Institute for Medical Research interviewed more than 2,000 Australian adults aged over 49 and followed them over [...]
Thu, Oct 18, 2018
Source WorldPharmaNews
AstraZeneca
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer. [...]
Thu, Oct 18, 2018
Source WorldPharmaNews
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,(1) shows that cutting-edge precision medicine is spreading from [...]
Wed, Oct 17, 2018
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews